Invisio delivers innovative medicines helping to transform peoples’ lives.

Creating and delivering practical solutions to problems brought about by the supply of straightforward treatments to patients.  Invisio improves the therapy experience of patients, resulting in better overall outcomes.  Transforming the delivery and optimizing therapy options, resulting in better value for money for payer authorities.

A dynamic and customer-focused team, Invisio brings a wealth of experience to drug profiling, development and, ultimately, delivery to the carers and patients.

Invisio develops partnerships with providers, working alongside healthcare provision organisations to ensure prices remain acceptable and realistic for all involved.

Russ PendletonRuss Pendleton, BSc MBA MIoD MBPsS

Experienced launch and commercialisation specialist. Particular expertise in the CNS field having launched three psychiatric drugs and managed two others. Also worked on therapies for neurological indications including Epilepsy, Stroke/TBI, Parkinson’s and Alzheimer’s Disease.

Initiated, managed and grown several conferences in CNS creating world-leading medical education events, these include Global Addiction, The International Review of Psychosis and Bipolarity, The Global College of Neuroprotection and Neuroregeneration and Winter Workshop in Schizophrenia.

Past editor of two journals; Aspects of Affect and International Journal of Neuroprotection and Neuroregeneration.

Inventor and entrepreneur with granted patents, and two developmental products that have been successfully out-licensed.  Russ studied Medical Science and Psychology at Newcastle University and added an MBA from Nottingham University Business School.

Bill GarnerBill Garner, MD MPH

Dr. William (Bill) Garner is a physician, investor and entrepreneur. Through EGB Ventures, Dr. Garner has made numerous public and private investments. Bill is currently Chairman of Race Oncology (ASX:RAC). Race Oncology is based on patents filed by EGB. Bill is Chairman of InMed Pharmaceuticals, Inc. (CSE:IN). Dr. Garner co-founded DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI).

Previously, Dr. Garner worked in medical affairs at Hoffmann LaRoche in oncology. Prior to Roche, Dr. Garner was a merchant banker in New York City. Dr. Garner has a Master of Public Health from Harvard and received his M.D. degree from New York Medical College. Dr. Garner did residency training in Anatomic Pathology at Columbia-Presbyterian and is currently a licensed physician in the State of New York. Among awards and honors, Dr. Garner was an AMA/Glaxo Wellcome Leadership Award recipient. Some of Dr. Garner’s research was funded by the American Federation for Aging Research.

Al HansenAl Hanson, AB MBA

Mr. Hansen is founder of KESA Partners, Inc., a private investment firm exclusively focused on investing in small companies in the pharma/medical device sector.

Mr. Hansen has over 30 years experience as a private equity investor and as an investment banker. He has been Chairman and/or CEO of a number of companies in the pharma/medical device sector including Questcor Pharmaceuticals, Cedarburg Pharmaceuticals, Molecular Medicine BioServices, Bioject and Bioserv. He has also served as a director of a number of other portfolio companies. KESA has also recently started several companies in the pharma/device sector. Mr. Hansen was previously a Managing Director at Signet Healthcare Partners and a Senior Vice President at Darby Overseas Investments.

He served as Director of Corporate Finance at the U.S. Treasury in the administration of George H. W. Bush. Prior to this, he was an investment banker with E.F. Hutton and Dillon Read. Mr. Hansen also served as a U.S. Army Special Forces officer.

Mr. Hansen has an A.B. from Princeton University and an M.B.A. (with distinction) from the Wharton School, University of Pennsylvania.